Simplified BALAD (BALAD‐S) Score as a Guide for First‐Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma
Hepatology Research · 2026-11 · 56 (11) · 1654-1664
DOI: 10.1111/hepr.70239 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatology Research, online erschienen am 16.07.2026. Verfasst von Atsushi Hiraoka und 57 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background and Aim Atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) are widely used first‐line immune checkpoint inhibitor (ICI)‐based regimens for unresectable hepatocellular carcinoma (uHCC). However, reliable biomarkers to inform treatment choice remain limited. This study evaluated whether the simplified BALAD‐based score (BALAD‐S) is associated with differential treatment outcomes. Materials and Methods This multicenter retrospective study included 752 Japanese patients with uHCC who received first‐line Atez/Bev ( n = 645) or Dur/Tre ( n = 107) between October 2020 and March 2026. BALAD‐S was calculated using bilirubin, albumin, AFP, AFP‐L3, and des‐γ‐carboxy prothrombin, and patients were stratified into BALAD‐S low (≤ 2) and high (≥ 3) groups. Treatment response, progression‐free survival (PFS), and overall survival (OS) were evaluated.
Results
In the BALAD‐S low group, Atez/Bev showed longer PFS than Dur/Tre (10.5 vs. 4.3 months; p < 0.001), with longer OS also observed (28.3 vs. 19.4 months; p = 0.049). In the BALAD‐S high group, PFS did not differ significantly (7.0 vs. 5.3 months with Dur/Tre and Atez/Bev, respectively, p = 0.210), whereas OS was longer with Dur/Tre than with Atez/Bev (27.3 vs. 16.4 months; p = 0.022). Treatment effects differed by BALAD‐S category (HR for Dur/Tre vs. Atez/Bev: 1.50 in BALAD‐S low and 0.55 in BALAD‐S high; p for interaction = 0.005). In patients treated from 2023 onward, similar treatment‐effect heterogeneity was observed (HR 1.61 in BALAD‐S low and 0.59 in BALAD‐S high; p for interaction = 0.007).
Conclusion
Outcomes with Atez/Bev and Dur/Tre differed according to BALAD‐S score. BALAD‐S may help identify patients with differential outcomes between first‐line ICI‐based regimens and represents a candidate stratification marker requiring validation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
- Department of Internal Medicine, Japanese Red Cross Himeji Hospital, Himeji, Japan.
- Department of Internal Medicine, Division of Gastroenterology, Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
- Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
- Department of Gastroenterology and Neurology, Kagawa University, Kagawa, Japan.
ORCID-Profile: Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hidenori Toyoda, Chikara Ogawa, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Tomomitsu Matono, Hidekatsu Kuroda, Yutaka Yata, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Yoshihide Ueda, Soo Ki Kim, Fujimasa Tada, Hideko Ohama, Shinichiro Nakamura, Takanori Matsuura, Yoshiko Nakamura, Osamu Yoshida, Kazuhiro Nouso, Asahiro Morishita, Taeang Arai, Akemi Tsutsui, Kazunari Tanaka, Yuki Kanayama, Hidenao Noritake, Jumpei Okamura, Kosuke Matsui, Masaki Kaibori, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada
Zitieren
APA
Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Nishimura, T., Tsuji, K., Ishikawa, T., Tajiri, K., Toyoda, H., Ogawa, C., Hatanaka, T., Kakizaki, S., Kawata, K., Naganuma, A., Kosaka, H., …, & RELPEC Group and the HCC 48 Group (2026). Simplified BALAD (BALAD‐S) Score as a Guide for First‐Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma. Hepatology Research, 56(11), 1654-1664. https://doi.org/10.1111/hepr.70239
Vancouver
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, et al. Simplified BALAD (BALAD‐S) Score as a Guide for First‐Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma. Hepatology Research. 2026;56(11):1654-1664. doi:10.1111/hepr.70239
BibTeX
@article{Hiraoka2026,
author = {Hiraoka, Atsushi and Tada, Toshifumi and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Nishimura, Takashi and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Toyoda, Hidenori and Ogawa, Chikara and Hatanaka, Takeshi and Kakizaki, Satoru and Kawata, Kazuhito and Naganuma, Atsushi and Kosaka, Hisashi and Matono, Tomomitsu and Kuroda, Hidekatsu and Yata, Yutaka and Nishikawa, Hiroki and Tanaka, Hironori and Imai, Michitaka and Aoki, Tomoko and Ochi, Hironori and Tamai, Hideyuki and Komatsu, Shohei and Ueda, Yoshihide and Kim, Soo Ki and Takaki, Shintaro and Tada, Fujimasa and Ohama, Hideko and Nakamura, Shinichiro and Matsuura, Takanori and Nakamura, Yoshiko and Yoshida, Osamu and Nouso, Kazuhiro and Morishita, Asahiro and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Tsutsui, Akemi and Nagano, Takuya and Tanaka, Kazunari and Koshiyama, Yuichi and Kanayama, Yuki and Noritake, Hidenao and Okamura, Jumpei and Enomoto, Hirayuki and Matsui, Kosuke and Kaibori, Masaki and Abe, Tamami and Hiasa, Yoichi and Kudo, Masatoshi and Kumada, Takashi and RELPEC Group and the HCC 48 Group, RELPEC Group and the HCC 48 Group},
title = {Simplified BALAD (BALAD‐S) Score as a Guide for First‐Line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma},
journal = {Hepatology Research},
year = {2026},
volume = {56},
number = {11},
pages = {1654--1664},
doi = {10.1111/hepr.70239}
}
EUVIMED